21022 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof Oxidoreductases (1)
Sub-classes:Constructs for Enhanced Production of Endothelial Nitric Oxide Synthase and Methods of Producing Cellular Compositions for Treatment of Pulmonary and Cardiac Diseases
#2METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV
#3METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#4ALDEHYDE DEHYDROGENASE PRODUCING BACTERIA AND METHODS OF USING SAME
#5REDUCING IMMUNOGENICITY TO PEGLOTICASE
#6URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
#7Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria
#8RETINAL PIGMENT EPITHELIAL (RPE) CELL-DIRECTED PEROXIDASE-BASED COMPOSITIONS, METHODS, AND SYSTEMS
#9PRODUCT AND PROCESS FOR MUCUS VISCOSITY NORMALIZATION
#10COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT
#11METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#12REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING
#13AAV PIGGYBAC TRANSPOSON POLYNUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREFOR
#14IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODS
#15ENTERIC AEROBIZATION THERAPY
#16METHODS AND COMPOSITIONS FOR METHIONINE RESTRICTION
#17USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE
#18CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#19NON-IMMUNOGENIC, HIGH DENSITY POEGMA CONJUGATES
#20METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID
#21PEROXIDASE BASED BIOCONTROL AGENTS
#22COMPOSITIONS AND METHODS FOR TREATING SOLID CANCER
#23GENETICALLY MODIFIED HUMAN STEM CELL EXPRESSING A MUTANT HUMAN CYTOCHROME P450 2B6 PROTEIN AND ITS USE THEREOF IN THE TREATMENT OF CANCER
#24COMPOSITION AND USE THEREOF FOR THE TREATMENT OF E. COLI INFECTION IN BOVINE CALVES
#25TARGETED INTEGRATION AT ALPHA-GLOBIN LOCUS IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS
#26COMPOSITIONS AND METHODS FOR THE MANAGEMENT AND TREATMENT OF PHENYLKETONURIA
#27METHOD OF PRODUCING PHYSIOLOGICAL AND THERAPEUTIC LEVELS OF NITRIC OXIDE THROUGH AN ORAL DELIVERY SYSTEM
#28COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES
#29ENGINEERING B CELL-BASED PROTEIN FACTORIES TO TREAT SERIOUS DISEASES
#30THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS
#31Dietary Supplement for Stimulating New Hair Growth and Reversing Hair Graying
#32COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS
#33DELIVERY OF THERAPEUTIC RECOMBINANT URICASE USING NANOPARTICLES
#34METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#35DESIGN AND CONSTRUCTION OF EVOLUTIONARY-GUIDED "SELECTION GENE DRIVE" THERAPY
#36METHOD FOR PRODUCING A STABILIZED DIAMINE OXIDASE LYOPHILISATE AND PHARMACEUTICAL DOSAGE FORM
#37METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY
#38METHODS FOR THE REDUCTION OF METHANE PRODUCTION IN RUMINANTS
#39BLOCK COPOLYMERS
#40HUMAN PAH EXPRESSION CASSETTE FOR TREATMENT OF PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY
#41THERAPEUTIC FACTORS FOR THE TREATMENT OF POLYQ DISEASES
#42COMPOSITION AND USE THEREOF FOR THE TREATMENT OF EQUINE GASTRIC ULCER SYNDROME
#43Encapsulation Method Using Extracellular Vesicle as Carrier
#44ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF
#45LYMPHATIC DELIVERY OF NANOPARTICLES TO TREAT NEURODEGENERATIVE, NEUROLOGICAL, AND EYE CONDITIONS
#46Method of Co-Expressing a Sulfatase and a Sulfatase Modifying Factor in a Plant or Plant Cell
#47NUCLEIC ACID ENCODING RRM2 SUBUNIT OF RIBONUCLEOTIDE REDUCTASE TO RESIST DEGRADATION
#48ENTERIC AEROBIZATION THERAPY
#49METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
#50METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
#51COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
#52DEGRADATION OF TOXINS IN VIVO
#53METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#54CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#55ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING PAH GENE FUNCTION AND METHODS OF USE THEREOF
#56FOOD COMPOSITION FOR IMPROVING BEHAVIORAL AND MOTOR FUNCTION CONTAINING ALDEHYDE DEHYDROGENASE FOR REDUCING ALDEHYDES PRODUCED BY OXIDATION OF AMINE
#57EXPRESSION VECTOR FOR CHOLESTEROL 24-HYDROLASE IN THERAPY OF POLYGLUTAMINE REPEAT SPINOCEREBELLAR ATAXIAS
#58FORMULATIONS AND DOSES OF PEGYLATED URICASE
#59ENGINEERED MICROORGANISM FOR TREATING HYPERPHENYLALANINEMIA AND USE THEREOF
#60MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#61FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOF
#62FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOF
#63MESSENGER RNA TREATMENT FOR SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY
#64USE OF THE 15-LIPOXYGENASE FOR THE TREATMENT OF LYMPHEDEMA
#65FORMULATIONS AND DOSES OF PEGYLATED URICASE
#66Gout flare prevention methods using IL-1BETA blockers
#67POLYPEPTIDE SEQUENCE OF KDM6B AND APPLICATION OF KDM6B IN REGULATING AND CONTROLLING FUNCTION OF MESENCHYMAL STEM CELL
#68READILY SOLUBLE AND THERMOSTABLE GLUCAGON FORMULATIONS AND DELIVERY FOR MINI-DOSING AND CLOSED -LOOP PROPHYLACTIC TREATMENT OF HYPOGLYCEMIA
#69GENE THERAPY IN SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD)
#70TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE)
#71THERAPY FOR PROGRAMMED CELL DEATH IN A SUBJECT TRANSPLANTED WITH A DONOR LIVER CARRYING THE PNPLA3 RS738409:G VARIANT
#72Enteric aerobization therapy
#73MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#74PROPEPTIDE OF LYSYL OXIDASE FOR TREATMENT OF CANCER
#75ALDEHYDE DEHYDROGENASE FOOD AND DRUG COMPOSITION FOR IMPROVING BEHAVIOR AND MOTOR FUNCTION
#76QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USES
#77Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V
#78METHODS AND COMPOSITIONS FOR TREATING HYPERGLYCEMIA AND DIABETES
#79AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE
#80ENZYME-LOADED POLYMERIC NANOPARTICLES AND METHODS OF MANUFACTURE AND USE OF SAME
#81MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#82BLOCK COPOLYMERS
#83METHODS FOR TREATING GOUT AND BONE DECALCIFICATION
#84Metal peroxide composite injectable hydrogel, preparation method and use thereof
#85STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
#86Aldehyde dehydrogenase producing bacteria and methods of using same
#87MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION
#88COMPOSITIONS AND METHODS FOR PROVIDING SECONDARY BILE ACIDS TO A SUBJECT
#89Methods for the reduction of methane production in ruminants
#90Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#91Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists
#92URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
#93TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE
#94Encapsulation of dual-enzyme composition for preventing, treating and/or alleviating veisalgia and symptoms associated therewith
#95GENE THERAPY FOR BCAA MODULATION IN MAPLE SYRUP URINE DISEASE (MSUD)
#96In Vitro Drugs from Prodrugs and Use Thereof
#97GENE THERAPIES FOR 21-HYDROXYLASE DEFICIENCY
#98FOOD AND DRUG COMPOSITION CONTAINING NOVEL ALDEHYDE DEHYDROGENASE FOR SUPPRESSING TREMOR OR MOVEMENT DISORDER
#99NOVEL ALDEHYDE DEHYDROGENASE FOOD AND DRUG COMPOSITION FOR IMPROVING BEHAVIOR AND MOTOR FUNCTION
#100COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING DUAL EXPRESSIONVECTOR FOR SIMULTANEOUSLY EXPRESSING PROTEIN PRESENT IN CELL AND PROTEIN SECRETED OUT OF CELL
#101GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERS
#102Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF/VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA2, or Esch
#103MODIFIED HUMAN SERUM ALBUMIN-THIOREDOXIN FUSION BODY
#104Compositions and Methods for Enhancing Anti-Viral Therapies
#105DETOXIFICATION PREPARATIONS WITH REINFORCED BOOSTERS TO TREAT ALCOHOL INTOXICATION
#106METHODS FOR REDUCING PATHOGENIC E COLI BY SELECTIVE FEED ADDITIVE INTERVENTION COMPRISING ENZYMES SUCH AS MURAMIDASE
#107Catechol Nanoparticle, Catechol Protein Nanoparticle, and Preparation Method and Use Thereof
#108COMPOSITION FOR USE AS AN ANTIVIRAL IN THE FORM OF NASAL DROPS AND IN NEBULISERS
#109SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS
#110NANOVESICULES DERIVING FROM BIOLOGICAL PLANTS AS NATURAL CARRIERS OF PHYTO-COMPLEXES FOR NUTRACEUTICAL, COSMETIC AND REGENERATIVE USE
#111Pharmaceutical composition and kit for treating gout
#112Process of Preparing mRNA-Loaded Lipid Nanoparticles
#113REDUCING IMMUNOGENICITY TO PEGLOTICASE
#114USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT
#115MODIFIED URICASE AND USES THEREOF
#116COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH AN IMPRINTING DEFECT
#117Quaternary tryptamines and their therapeutic uses
#118CONTROL OF HISTAMINE TO PROMOTE HEALTH AND CONTROL ENTEROCOLITIS USING PROBIOTIC COMPOSITIONS
#119ANTIVIRAL AGENTS
#120PARAPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING, COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING BIOFILM FORMATION
#121GENE THERAPEUTICS FOR ENHANCEMENT/RESTORATION OF ENDOMETRIAL FUNCTION
#122CORE-SHELL MICRONEEDLE DEVICES AND USES THEREOF
#123New Granules for Animal Feed
#124MICROPARTICLE-BASED ENZYME SYSTEMS FOR SELECTIVE REMOVAL OF TARGET MOLECULES
#125METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE
#126AMERICAN CHESTNUT LEAF COMPOSITIONS COMPRISING OXALATE OXIDASE AND METHODS FOR TREATMENT OF OXALATE-RELATED DISORDERS
#127METHODS OF TREATING GOUT
#128COMPOSITIONS AND METHODS FOR REDUCING URIC ACID CONCENTRATION USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM
#129COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS
#130Adeno-associated virus variant capsids and methods of use thereof
#131Enteric aerobization therapy
#132THERAPEUTIC MICROBES
#133Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#134COMPOSITE NANOMATERIAL BASED ON METAL-ORGANIC FRAMEWORK MATERIAL LOADED WITH HORSERADISH PEROXIDASE AND PREPARATION METHOD AND USE THEREOF
#135URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
#136COMPOSITION FOR TREATMENT OF GLUTARIC ACIDURIA AND ADMINISTRATION METHOD THEREFOR
#137STABLE PEPTIDES HAVING RENALASE AGONIST ACTIVITY
#138Enteric aerobization therapy
#139METHODS FOR TREATING PLASMA PROTEIN IMBALANCES OR DEPLETION
#140REDUCING IMMUNOGENICITY TO PEGLOTICASE
#141COMPOSITIONS AND METHODS FOR DISRUPTING BIOFILM FORMATION AND MAINTENANCE
#142Urate oxidase-albumin conjugate, preparation method thereof, and use thereof
#143BLOCKING A PATHOGEN FROM EXPRESSING A VIRULENCE FACTOR
#144Dual-enzyme composition for preventing, treating and/or alleviating veisalgia and symptoms associated therewith
#145USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT
#146PEROXIREDOXIN 6 OR A SYNTHETIC ANALOGUE THEREOF FOR USE AS A HYPOGLYCAEMIC AGENT
#147GENE THERAPY FOR MAPLE SYRUP URINE DISEASE
#148METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES
#149N6-Methyladenosine Regulators in Uterine Fibroids
#150Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
#151METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#152RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH URIC ACID AND METHODS OF USE THEREOF
#153ADVANCED MICROBIOME THERAPEUTICS ENGINEERED TO PRODUCE SEROTONIN IN VIVO
#154ADENO-ASSOCIATED VIRUS FORMULATIONS
#155METHODS OF REACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS AND RELATED COMPOSITIONS
#156INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#157IMPROVED URICASE AND METHOD FOR TREATING HYPERURICEMIA USING SAME
#158STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#159COMPOSITIONS AND METHODS FOR REGULATING FATTY ACIDS
#160MRNA THERAPY FOR PHENYLKETONURIA
#161Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions
#162Variant forms of urate oxidase and use thereof
#163Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#164Recombinant Heme Oxygenase-1 (HO-1) for the Treatment of Sickle Cell Disease
#165CONTROL OF HISTAMINE TO PROMOTE HEALTH AND CONTROL ENTEROCOLITIS USING PROBIOTIC COMPOSITIONS AND/OR HISTAMINE DEGRADING ENZYMES
#166SELF-ASSEMBLED CATALASE NANOPARTICLE AND PREPARATION METHOD THEREFOR AND USE THEREOF
#167CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#168REDUCING IMMUNOGENICITY TO PEGLOTICASE
#169Oral delivery system for bioactive agents
#170NEURONAL VIABILITY FACTOR AND USE THEREOF
#171THERAPEUTIC COMPOSITIONS AND METHODS OF USING SEROTONIN MODULATING MICROBIOME-BASED INTERVENTIONS TO TREAT SEROTONIN-RELATED DISEASES OR DISORDERS
#172BIOACTIVE NANOPARTICLE COMPOSITIONS AND METHODS FOR MAKING SAME
#173GINGER DERIVED EXTRACELLULAR VESICLES AND USE THEREOF
#174METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV
#175PHARMACEUTICAL PREPARATIONS AND METHODS TO MANAGE WEIGHT AND TO MODULATE THE GUT MICROBIOTA
#176COMPOSITION FOR PREVENTING, TREATING, OR AMELIORATING VIRAL INFECTION DISEASE, CONTAINING ACTIVE OXYGEN PRODUCTION INHIBITOR AND ACTIVE OXYGEN SCAVENGER COMPLEX AS ACTIVE INGREDIENTS
#177PEGLOTICASE FOR TREATMENT OF GOUT IN RENAL TRANSPLANT RECIPIENTS
#178REDUCING IMMUNOGENICITY TO PEGLOTICASE
#179Methods of treating spinal cord injury
#180APPLICATION OF FLAVIN-CONTAINING MONOOXYGENASE 2 (FMO2) IN PREPARING DRUG FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
#181HIGH EFFICIENCY OXALATE-DEGRADING ENZYMES FOR DEGRADATION OF INSOLUBLE AND SOLUBLE OXALATE
#182VACCINE FORMULATIONS
#183Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG
#184PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR
#185REGULATION OF GENE EXPRESSION BY APTAMER-MEDIATED MODULATION OF ALTERNATIVE SPLICING
#186Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders
#187Method of co-expressing a sulfatase and a sulfatase modifying factor in a plant or plant cell
#188Adeno-associated virus variant capsids and methods of use thereof
#189VECTORS AND METHODS FOR REGENERATIVE THERAPY
#190TOPICAL COMPOSITIONS COMPRISING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH HIGH HISTAMINE LEVELS WHICH INVOLVE AN INCREASE IN PAIN
#191REDOX ENZYMES IN ANIMAL FEED COMPOSITIONS
#192OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTES AND THEIR USE
#193Ophthalmic treatment device, system, and method of use
#194CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF
#195Pyocyanine Demethylases and related Phenazine Degrading Agents Compositions, Methods and Systems for Interfering with Viability of Bacteria
#196BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID
#197GLUCOSE-RESPONSIVE INSULIN DELIVERY MICRONEEDLE SYSTEM
#198GENE THERAPY METHODS
#199Functional foods comprising diamine oxidase and uses thereof
#200METHODS AND SYSTEMS FOR IDENTIFYING MODULATORS OF PERVASIVE DEVELOPMENTAL DISORDERS
#201ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES
#202Method for preparing a bone protein preparation and a bone protein preparation
#203Human PAH expression cassette for treatment of PKU by liver-directed gene replacement therapy
#204POLYNUCLEOTIDES ENCODING VERY LONG-CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY
#205METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
#206MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF
#207Agent for use in the case of fructose intolerance
#208POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE
#209EXPRESSION VECTOR FOR CHOLESTEROL 24-HYDROLASE IN THERAPY OF AMYOTROPHIC LATERAL SCLEROSIS
#210PHARMABIOTIC TREATMENTS FOR METABOLIC DISORDERS
#211A COMPOSITION FOR CANCER CELL DEATH AND ITS USE
#212Nicotine degrading enzyme variants
#213URICASE GEL PREPARATION FOR EXTERNAL USE, PREPARATION METHOD THEREFOR AND USE THEREOF
#214MARKER FOR DIAGNOSING NEURODEGENERATIVE DISEASE, AND THERAPEUTIC COMPOSITION
#215METHODS FOR DESENSITIZATION OF URICASE
#216FUSOSOME COMPOSITIONS FOR CNS DELIVERY
#217COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING AND DIAGNOSIS OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES
#218IMMUNOGENIC PEPTIDES WITH IMPROVED OXIDOREDUCTASE MOTIFS
#219Method of treating AML subtypes using arginine-depleting agents
#220Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
#221Adeno-associated virus variant capsids and methods of use thereof
#222BIOMATERIAL-BASED COVID-19 VACCINE
#223GENERATION OF IMPROVED HUMAN PAH FOR TREATMENT OF SEVERE PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY
#224METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
#225USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASE
#226HALOPEROXIDASE COMPOSITIONS AND USES THEREOF
#227METHODS OF TREATING AN AUTOIMMUNE DISEASE
#228Method for visually enhancing the experience of an audience during a performance
#229METHODS AND USES OF COLCHICINE DERIVATIVES
#230Product and Process for Mucus Viscosity Normalization
#231Methods and compositions related to physiologically responsive microneedle delivery systems
#232Microparticle-based enzyme systems for selective removal of target molecules
#233MODIFIED RNA WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
#234FORMULATIONS AND DOSES OF PEGYLATED URICASE
#235Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#236Methods and compositions to modulate the gut microbiota and to manage weight
#237SYSTEMS AND METHODS FOR LYSOSOME INDUCED IMMUNOGENIC CELL DEATH
#238Mitochondrial localization signals in human tafazzin and uses thereof
#239Larval preparation of Heligmosomoides polygyrus bakeri as well as methods of making it and uses thereof
#240Methods and compositions to modulate the gut microbiota and to manage weight
#241METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT
#242Ocular applications of matrix bound vesicles (MBVs)
#243Interactional Biosystem
#244Methods and Compositions for Treating Phenylketonuria
#245MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#246TREATMENT OF MICROBIAL INFECTIONS
#247MATRIX BOUND VESICLES (MBVS) CONTAINING IL-33 AND THEIR USE
#248Variant forms of urate oxidase and use thereof
#249Methods and compositions for treatment of ocular disorders and blinding diseases
#250AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY
#251BLOCKING A GRAM-NEGATIVE BACTERIA FROM EXPRESSING A VIRULENCE FACTOR
#252Lipid-derived neutral nanoparticles
#253Phenazine degrading agents and related compositions, methods and systems for interfering with viability of bacteria
#254RNA preparations comprising purified modified RNA for reprogramming cells
#255Block copolymers
#256Immunosuppressive materials and related methods
#257METHOD OF PRODUCING PHYSIOLOGICAL AND THERAPEUTIC LEVELS OF NITRIC OXIDE THROUGH AN ORAL DELIVERY SYSTEM
#258NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE
#259TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS
#260A HEPATOCYTE-MIMICKING ANTIDOTE FOR ALCOHOL INTOXICATION
#261FORMULATIONS AND DOSES OF PEGYLATED URICASE
#262GENE SEQUENCE CONSTRUCT USED FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
#263Acute Respiratory Distress Syndrome Therapeutic Agent
#264Compositions and methods for treating or preventing diseases associated with oxidative stress
#265MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#266REDUCING IMMUNOGENICITY TO PEGLOTICASE
#267EXTRACELLULAR MATRIX AND ITS USE FOR REGULATING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS
#268SYSTEMS, METHODS, AND COMPOSITIONS TO IDENTIFY NEW PROTEIN TARGETS OF A CHEMICAL COMPOUND OR ITS DERIVATIVES
#269Adeno-associated virus virion for gene transfer to nervous system cells
#270Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
#271Modulation of gene expression in a human bioreactor
#272METHODS OF DIAGNOSIS AND TREATMENT INVOLVING NITRITE
#273Method for preparing a bone protein preparation and a bone protein preparation
#274Compositions and methods for the treatment of cancer
#275METHODS OF REACTIVATING LATENT HUMAN IMMUNODEFICIENCY VIRUS AND RELATED COMPOSITIONS
#276Use of ALDH1A and agonist, catalyst and inhibitor thereof
#277Lipid supplements for reducing nerve action potentials
#278MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#279VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF
#280REDUCING IMMUNOGENICITY TO PEGLOTICASE
#281REDUCING IMMUNOGENICITY TO PEGLOTICASE
#282Methods for treating gout
#283TOPICAL COMPOSITIONS COMPRISING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH HIGH HISTAMINE LEVELS WHICH INVOLVE AN INCREASE IN PAIN
#284PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR
#285ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING
#286Compositions and methods for treating diseases associated with an imprinting defect
#287Neuronal viability factor and use thereof in Alzheimer's disease
#288Multimeric coding nucleic acid and uses thereof
#289CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#290Composition for transdermal delivery of glutathione
#291Methods to improve beverage quality
#292METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO ENERGY FAILURE
#293Stable Bioactive Substances and Methods of Making
#294Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation
#295STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#296FORMULATION AND METHOD FOR PROMOTING HAIR GROWTH
#297CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
#298Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
#299Regulation of gene expression by aptamer-mediated modulation of alternative splicing
#300METHODS OF ATTACHING A MOLECULE-OF-INTEREST TO A MICROTUBE